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Benjamin J. Lee1,2,3, Chi-yuan Hsu1,4, Rishi Parikh4, Charles E. McCulloch5, Thida C. Tan4,
Kathleen D. Liu1,6, Raymond K. Hsu1, Leonid Pravoverov7, Sijie Zheng4,7 and Alan S. Go1,4,5
1Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA;
2Houston Kidney Consultants, Houston, Texas, USA; 3Houston Methodist Institute for Academic Medicine, Houston, Texas,
USA; 4Division of Research, Kaiser Permanente Northern California, Oakland, California, USA; 5Department of Epidemiology
and Biostatistics, University of California, San Francisco, San Francisco, California, USA; 6Division of Critical Care, Department
of Anesthesia, University of California, San Francisco, San Francisco, California, USA; and 7Department of Nephrology, Kaiser
Permanente Oakland Medical Center, Oakland, California, USAIntroduction: After dialysis-requiring acute kidney injury (AKI-D), recovery of sufficient kidney function to
discontinue dialysis is an important clinical and patient-oriented outcome. Predicting the probability of
recovery in individual patients is a common dilemma.
Methods: This cohort study examined all adult members of Kaiser Permanente Northern California who
experienced AKI-D between January 2009 and September 2015 and had predicted inpatient mortality
of <20%. Candidate predictors included demographic characteristics, comorbidities, laboratory values,
and medication use. We used logistic regression and classification and regression tree (CART) approaches
to develop and cross-validate prediction models for recovery.
Results: Among 2214 patients with AKI-D, mean age was 67.1 years, 40.8% were women, and 54.0% were
white; 40.9% of patients recovered. Patients who recovered were younger, had higher baseline estimated
glomerular filtration rates (eGFR) and preadmission hemoglobin levels, and were less likely to have prior
heart failure or chronic liver disease. Stepwise logistic regression applied to bootstrapped samples
identified baseline eGFR, preadmission hemoglobin level, chronic liver disease, and age as the predictors
most commonly associated with coming off dialysis within 90 days. Our final logistic regression model
including these predictors had a correlation coefficient between observed and predicted probabilities of
0.97, with a c-index of 0.64. An alternate CART approach did not outperform the logistic regression model
(c-index 0.61).
Conclusion: We developed and cross-validated a parsimonious prediction model for recovery after AKI-D
with excellent calibration using routinely available clinical data. However, the model’s modest discrimi-
nation limits its clinical utility. Further research is needed to develop better prediction tools.
Kidney Int Rep (2019) 4, 571–581; https://doi.org/10.1016/j.ekir.2019.01.015
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ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).A KI-D is a serious acute medical condition that af-fects 3% to 13% of critically ill patients.1–3
Although in-hospital mortality among patients with
AKI-D has declined,4–8 a sizeable fraction of survivors
remain dialysis-dependent at the time of hospital
discharge and beyond.2,5,9–11 Renal recovery after AKI-
D, defined as return of sufficient kidney function to dis-
continue dialysis, is an important clinical and patient-
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International Reports (2019) 4, 571–581oriented outcome. Although most patients with normal
baseline kidney function eventually recover if they sur-
vive the AKI-D hospitalization,12 many patients with
AKI-D experience acute kidney injury (AKI) superimposed
on chronic kidney disease (CKD) and do not recover.13–15
Prediction of recovery after the onset of AKI-D is a
common dilemma confronted by patients, their families,
and physicians across multiple specialties, from ne-
phrologists to intensivists, hospitalists, and primary care
physicians. Baseline eGFR, proteinuria, age, diabetes
mellitus, and comorbidity burden have been shown to
influence the probability of recovery.9,10,13–17 The only
published prediction model was constructed by Srisawat
et al.,18 who found that Charlson comorbidity index and
APACHE II score were predictors. However, their study
was small (n ¼ 76) and included only highly selected571
CLINICAL RESEARCH BJ Lee et al.: Predicting Recovery After AKI-Dparticipants enrolled in a clinical trial that excluded pa-
tients with preexisting stage 4 or 5 CKD, so generaliz-
ability was limited for multiple reasons.19,20 Overall, data
on the natural history of AKI-D are variable, and it is
difficult to know whether an individual patient with
AKI-D will recover.9,21
The ability to predict recovery more accurately
could potentially guide counseling and decision-
making in both the inpatient and outpatient set-
tings. Many hospitalized patients with AKI ask about
their chances of recovery even before initiating acute
dialysis, and some may decline starting dialysis alto-
gether if they understand that the chances of recovery
are very low and they will likely be on dialysis for the
rest of their lives. Accurate prediction of recovery
would inform dialysis access decisions for patients
with AKI-D: both the choice of temporary versus
tunneled catheters in the short-term and the timing of
fistula or graft placement in the medium-term.
Improved prognostic abilities would also influence
the timing of outpatient dialysis chair placement (i.e.,
establishing a time and location for outpatient dial-
ysis), which could potentially affect hospital length of
stay. In the outpatient setting, when patients consider
procedures that may prolong AKI-D (e.g., iodinated
contrast administration), the ability to predict recov-
ery would help patients and their providers appro-
priately weigh risks and benefits. From a research
perspective, improved prognostic abilities would
allow for targeted enrollment of patients with AKI-D
who have a reasonable chance of recovery into trials
testing potential treatments.
There are currently no validated AKI-D recovery
prediction models, and expert panels have identified
this knowledge gap as a key barrier to improving out-
comes in this vulnerable population.9,22 Using a diverse,
community-based cohort, our objective was to develop a
prediction model for recovery after AKI-D that would be
applicable to routine clinical practice.METHODS
Source Population
The source population was based within Kaiser Per-
manente Northern California (KPNC), a large, integrated
health care delivery system that provides comprehen-
sive care for >4.4 million members. These patients
were treated in 21 Kaiser Permanente–owned hospitals
(Supplementary Appendix S1). The KPNC membership
is highly representative of the surrounding local and
statewide populations.23 Nearly all aspects of care are
captured through KPNC’s electronic medical record
system, which is integrated across inpatient, emergency
department, and outpatient care settings.572This study was approved by the institutional review
boards at KPNC and the University of California, San
Francisco, with waiver of informed consent obtained
because of the nature of the study.
Study Sample
We conducted a retrospective cohort study of all adult
(age $18 years) KPNC members who developed AKI-D
between January 1, 2009, and September 30, 2015, and
who had $12 consecutive months of health plan mem-
bership and pharmacy benefits before the index hospi-
talization to ensure adequate capture of relevant
comorbidities, laboratory tests, and prescription medi-
cation use. For this analysis, we classified patients as
having AKI-D if they underwent renal replacement
therapy (RRT; acute intermittent hemodialysis and/or
continuous RRT) during hospitalization in the absence of
any preadmission chronic RRT and had peak inpatient
serum creatinine concentration $50% of preadmission
baseline (defined as the most recent non–emergency
department outpatient measurement between 7 and
365 days before admission). Chronic RRT before
admission was ascertained through a comprehensive
KPNC End-Stage Renal Disease (ESRD) Treatment Regis-
try that tracks initiation and cessation of RRT treatments
and date(s) of renal transplantation.13,15,24,25 We
excluded patients who had baseline eGFR values <15
ml/min per 1.73 m2 (because it is difficult in this eGFR
range to distinguish true AKI-D from progression of
severe CKD) or predicted probability of inpatient
mortality $20% using a KPNC-validated risk score26
(because the issue of renal recovery is clinically rele-
vant only among those patients with AKI-D who are
likely to survive the acute hospitalization and also to
reduce analytic issues introduced when death can be
interpreted as a state of “nonrecovery” after AKI-D).
We also conducted 2 sensitivity analyses: one that
did not exclude patients with predicted probability of
inpatient mortality $20% and one that used serum
creatinine instead of eGFR.
Renal Recovery After AKI-D
The primary outcome was recovery of native kidney
function after AKI-D, defined as RRT independence
within 90 days after RRT initiation and survival
for $4 weeks after RRT discontinuation. Patients
who stopped RRT within 4 weeks of the 90-day cutoff
were observed past 90 days to confirm that they
remained alive for the minimum 4-week period. We
used status at 90 days because patients are conven-
tionally considered to have ESRD if they remain
dialysis-dependent for $90 days.9 We required that
patients be alive and off dialysis for $4 weeks
to reduce potential misclassification of people whoKidney International Reports (2019) 4, 571–581
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Recovery could occur during the initial AKI-D hospi-
talization or in the outpatient setting after hospital
discharge. We anchored our analysis based on the date
of RRT initiation (rather than hospital discharge or
some other date) to link it more closely to the natural
history of the AKI episode rather than other extraneous
factors that may influence length of hospitalization.Table 1. Selected baseline characteristics of adults with dialysis-requirin
Variablea
Overall
(N [ 2214)
Age, yr 67.1 (13.1)
Women, n (%) 904 (40.8)
Self-reported race, n (%)
White 1195 (54.0)
Black/African American 281 (12.7)
Asian/Pacific Islander 268 (12.1)
Other/Unknown 470 (21.2)
Hispanic ethnicity, n (%) 408 (18.4)
Medical history, n (%)
Acute myocardial infarction 127 (5.7)
Coronary artery bypass graft surgery 35 (1.6)
Stroke or transient ischemic attack 90 (4.1)
Heart failure 750 (33.9)
Diabetes mellitus 1269 (57.3)
Hypertension 1862 (84.1)
Chronic liver disease 181 (8.2)
Body mass index, kg/m2 31.3 (8.6)
Predicted probability of inpatient mortalityb 0.1 (0.0)
Preadmission medication use, n (%)
ACE inhibitor 806 (36.4)
Angiotensin II receptor blocker 384 (17.3)
Diuretic 1403 (63.4)
Any antihypertensive agent 1944 (87.8)
Nonsteroidal anti-inflammatory drug 186 (8.4)
Diabetic therapy 823 (37.2)
Laboratory values
Preadmission eGFR, ml/min per 1.73 m2
60–150 777 (35.1)
45–59 367 (16.6)
30–44 461 (20.8)
15–29 609 (27.5)
Preadmission creatinine, mg/dl 1.6 (0.8)
Median (25th–75th percentile) 1.4 (1.0–2.1)
Preadmission dipstick proteinuria, n (%)
Negative/Trace 289 (13.1)
1þ 278 (12.6)
$2þ 457 (20.6)
Unknown 1190 (53.7)
Preadmission hemoglobin, g/dl 11.7 (2.0)
Preadmission serum albumin, g/dl 3.6 (0.7)
Preadmission platelet count,  103/ml
>400 108 (4.9)
150–400 1421 (64.2)
<150 399 (18.0)
Peak inpatient serum creatinine, mg/dl 5.7 (2.8)
ACE, angiotensin-converting enzyme; eGFR, estimated glomerular filtration rate.
aMean (SD) unless otherwise indicated.
bProbability range 0 to 1.
Kidney International Reports (2019) 4, 571–581Covariates
Demographic characteristics (e.g., age, gender, self-
reported race and ethnicity) were obtained from
health plan databases.27–29 Relevant comorbidities were
defined by diagnostic or procedural International
Classification of Diseases, Ninth Revision codes and
supplemented with laboratory test results, outpatient
vital signs, and prescribed medications using electronicg acute kidney injury, stratified by renal recovery status
Not recovered Recovered
P(n [ 1309) (n [ 905)
67.9 (13.1) 66.0 (13.1) <0.001
546 (41.7) 358 (39.6) 0.31
0.82
696 (53.2) 499 (55.1)
167 (12.8) 114 (12.6)
162 (12.4) 106 (11.7)
284 (21.7) 186 (20.6)
254 (19.4) 154 (17.0) 0.15
83 (6.3) 44 (4.9) 0.14
19 (1.5) 16 (1.8) 0.56
55 (4.2) 35 (3.9) 0.70
495 (37.8) 255 (28.2) <0.001
770 (58.8) 499 (55.1) 0.08
1108 (84.6) 754 (83.3) 0.40
131 (10.0) 50 (5.5) <0.001
30.8 (8.5) 32.1 (8.7) <0.001
0.1 (0.0) 0.1 (0.0) 0.90
455 (34.8) 351 (38.8) 0.05
220 (16.8) 164 (18.1) 0.42
866 (66.2) 537 (59.3) 0.001
1155 (88.2) 789 (87.2) 0.46
92 (7.0) 94 (10.4) 0.005
503 (38.4) 320 (35.4) 0.14
389 (29.7) 388 (42.9) <0.001
190 (14.5) 177 (19.6)
277 (21.2) 184 (20.3)
453 (34.6) 156 (17.2)
1.7 (0.8) 1.4 (0.7) <0.001
1.5 (1.0–2.3) 1.2 (1.0–1.8) <0.001
164 (12.5) 125 (13.8) <0.001
170 (13.0) 108 (11.9)
307 (23.5) 150 (16.6)
668 (51.0) 522 (57.7)
11.5 (1.9) 12.1 (2.1) <0.001
3.5 (0.7) 3.7 (0.7) <0.001
<0.001
68 (5.2) 40 (4.4)
823 (62.9) 598 (66.1)
270 (20.6) 129 (14.3)
5.6 (2.7) 5.9 (2.9) 0.02
573
Table 2. Multivariable predictors of renal recovery after dialysis-
requiring acute kidney injury
Variable Adjusted odds ratio (95% CI)
Age, yr
18–40 Ref
41–60 1.40 (0.87–2.26)
61–75 1.09 (0.68–1.73)
>75 0.85 (0.53–1.38)
Chronic liver disease 0.46 (0.32–0.65)
Preadmission CKD-EPI eGFR category,
ml/min per 1.73 m2
60–150 Ref
45–59 1.05 (0.81–1.36)
30–44 0.77 (0.60–0.99)
15–29 0.41 (0.32–0.53)
Preadmission hemoglobin, g/dl
$14 Ref
13.0–13.9 0.76 (0.53–1.08)
12.0–12.9 1.14 (0.82–1.58)
11.0–11.9 0.61 (0.44–0.85)
10.0–10.9 0.81 (0.57–1.14)
9.0–9.9 0.61 (0.42–0.89)
<9.0 0.62 (0.40–0.97)
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration;
eGFR, estimated glomerular filtration rate.
Figure 1. Cohort assembly for adults experiencing dialysis-requiring acu
KPNC, Kaiser Permanente Northern California.
CLINICAL RESEARCH BJ Lee et al.: Predicting Recovery After AKI-D
574health record–based data that were cleaned and linked
at the individual-patient level into the Kaiser Perma-
nente Virtual Data Warehouse as previously described
and validated.25,30–38 Patient vital status was deter-
mined using comprehensive information from health
plan administrative and clinical databases, member
proxy reporting, Social Security Administration vital
status files, and California state death certificate infor-
mation.39,40 Demographic characteristics and inpatient
laboratory values were measured on the date of RRT
initiation for AKI-D, and baseline outpatient laboratory
values and vital signs were measured 7 to 365 days
before admission. For variables that had missing data, a
category for missingness was created for each of those
variables. Variables with >20% of values missing were
not included in the modeling process.Statistical Approach
Analyses were conducted using SAS, version 9.3 (SAS
Inc., Cary, NC) and Salford Predictive Modeler, version
8.2 (Salford Systems, San Diego, CA). Baseline charac-
teristics were compared across recovery groups usingte kidney injury (AKI-D). eGFR, estimated glomerular filtration rate;
Kidney International Reports (2019) 4, 571–581
Figure 2. Calibration curve for predicted and observed probabilities of renal recovery using 10-fold cross-validation, by decile of predicted
probability.
BJ Lee et al.: Predicting Recovery After AKI-D CLINICAL RESEARCHanalysis of variance for continuous variables and c2
tests for categorical variables.
We initially conducted a multivariable logistic
regression analysis for prediction of recovery after
AKI-D, with the following candidate predictors: age,
gender, self-reported race and ethnicity, smoking
status, preadmission medication use, preexisting
comorbidities (heart failure, coronary heart disease,
prior ischemic stroke, peripheral artery disease, atrial
fibrillation, mitral or aortic valvular disease, venous
thromboembolism, hypertension, diabetes mellitus,
dyslipidemia, prior hospitalized gastrointestinal
bleed, thyroid disease, chronic liver disease, chronic
lung disease, dementia, depression), and inpatient
mortality risk score.26 Additional candidate pre-
dictors included the following preadmission vari-
ables: body mass index, systolic blood pressure,
preadmission high-density and low-density lipopro-
tein levels, eGFR (using the Chronic Kidney Disease
Epidemiology Collaboration creatinine equation41),
dipstick proteinuria level, hemoglobin level, and
platelet count. Body mass index, preadmission sys-
tolic blood pressure, and all laboratory-based vari-
ables were treated as ordinal categorical variables
(partitions between categories shown in Tables 1 and
2; similar results were obtained when these covariates
were treated as continuous variables). To identifyKidney International Reports (2019) 4, 571–581important predictors, we first generated 1000 random
samples of the analytic cohort through bootstrap
resampling with replacement and then conducted
automated stepwise logistic regression on each sam-
ple. Predictors that were selected by stepwise
regression in $75% of the bootstrapped samples were
included in the final model. We subsequently used
10-fold cross-validation to generate predicted proba-
bilities of recovery for each patient, which were used
to calculate a c-index and generate calibration statis-
tics. Finally, model parameter estimates and odds ra-
tios for the final set of predictors were generated
through a logistic regression model using the full
analytic cohort.
We also planned a priori to perform a CART anal-
ysis for recovery because it was not known whether
this method would yield more clinically useful results
than the logistic regression approach.42 Candidate
predictors were the same as those used in the logistic
regression analysis. CART treated all laboratory
values as continuous variables and optimally selected
cut-points to minimize information loss. No limits
were set on minimum node or terminal size. Trees
were pruned and optimized using built-in 10-fold
cross-validation to minimize the relative misclassifi-
cation of cases while protecting against overfitting. C-
indices, a confusion matrix, and a receiver operating575
CLINICAL RESEARCH BJ Lee et al.: Predicting Recovery After AKI-Dcharacteristic curve were generated to evaluate per-
formance of the final decision tree.RESULTS
Cohort Assembly and Baseline Characteristics
We initially identified 13,213 adult patients who
received inpatient RRT. After excluding patients who
received chronic dialysis before hospitalization, were of
age <18 years, had unknown gender, had <12 consec-
utive months of membership or drug coverage before the
index hospitalization, had no baseline serum creatinine
concentration, had baseline eGFR >150 or <15 ml/min
per 1.73 m2, had a predicted probability of inpatientFigure 3. Classification and regression tree decision tree for recovery aft
filtration rate.
576mortality $20%, or had <50% increase in peak inpa-
tient serum creatinine concentration compared with
preadmission baseline, we had a final analytic cohort of
2214 patients with AKI-D (Figure 1).
Mean age was 67.1 years, 40.8% were women, and
54.0% were white. Overall, 905 (40.9%) patients
recovered within 90 days of RRT initiation. Of the pa-
tients who did not recover, 731 (55.8%) died while still
dialysis-dependent. Selected candidate predictors are
presented in Table 1; the remaining additional candidate
predictors are reported in Supplementary Table S1.
Compared with patients who did not recover, patients
who recovered were younger and less likely to have a
history of heart failure or chronic liver disease. Thoseer dialysis-requiring acute kidney injury. eGFR, estimated glomerular
Kidney International Reports (2019) 4, 571–581
BJ Lee et al.: Predicting Recovery After AKI-D CLINICAL RESEARCHwho recovered had a higher body mass index, higher
baseline eGFR, less proteinuria, and higher preadmission
hemoglobin level (Table 1).
Logistic Regression
In 1000 bootstrap samples of the analytic cohort, 4
predictors were chosen by stepwise regression in
>75% of samples: baseline (preadmission) eGFR (all
1000 samples), preadmission hemoglobin level (954
samples), history of chronic liver disease (863 samples),
and age (802 samples). The c-index of a model with
these predictors, obtained using observed and pre-
dicted values from 10-fold cross-validation, was 0.64.
The correlation coefficient (R) between observed and
predicted probabilities of recovery, plotted by decile of
predicted probability of recovery, was high at 0.97
(Figure 2). Predicted recovery probabilities ranged
from 9% to 22% in the lowest decile to 58% to 66% in
the highest decile. Using the full analytic cohort, we
obtained odds ratios for recovery for the 4 chosen
predictors using logistic regression (Table 2).
In our sensitivity analysis that did not exclude pa-
tients with predicted probability of inpatient
mortality $20%, the same predictors were chosen us-
ing our bootstrapping and cross-validation approach,
with no significant change in the c-index (0.645).
In an additional sensitivity analysis, results did not
materially differ if serum creatinine concentration was
used instead of eGFR (c-index 0.646), and the same
predictors were selected.
CART Analysis
The final decision tree included 4 nodes: eGFR $30 ml/
min per 1.73 m2, preadmission hemoglobin <12.0 g/l,
preadmission platelet count $150,000/ml, and history
of diabetes mellitus (Figure 3). CART subdivided the
cohort into 5 risk groups with recovery probabilities
ranging from 25.6% to 52.7%. The c-index obtained
from 10-fold cross-validation was 0.61.
CONCLUSION
We developed and cross-validated a parsimonious lo-
gistic regression model for recovery after AKI-D using
variables that are routinely available in clinical practice.
To our knowledge, our study is the first to develop a
recovery prediction model that uses clinical data from a
diverse, community-based cohort. Although novel,
simple to use, and having excellent calibration (i.e.,
ability to predict absolute risk accurately), our model
demonstrated only modest discrimination, which limits
its clinical utility.
We believe that our model’s disappointing discrim-
ination highlights how very challenging it is to
distinguish relatively between patients with higherKidney International Reports (2019) 4, 571–581versus lower chances of recovery in a real-world clin-
ical setting using information currently available to
physicians. This finding is entirely concordant with
our recent report that approximately 1 in every 24
patients registered as having ESRD in the U.S. Renal
Data System recovered to discontinue dialysis and
likely had AKI-D misclassified as permanent kidney
failure instead.43 This dilemma has population-level
implications, particularly in the United States where
reimbursement policies for dialysis services have his-
torically differed depending on whether a patient is
designated as having AKI-D or ESRD. The Centers for
Medicare and Medicaid Services only reinstated reim-
bursement for dialysis provided to AKI-D outpatients
in 2017, and payments for skilled nursing facility res-
idents with AKI-D only started in 2018.44 Furthermore,
there has been considerable debate regarding whether
patients with AKI-D should be included in the ESRD
Quality Incentive Program, which affects payments to
ESRD facilities.45 Because optimal clinical management of
patients with AKI-D and of patients with ESRD differ,
the American Society of Nephrology46 and Renal Phy-
sicians Association47 have strongly advocated against
including patients with AKI-D in the ESRD Quality
Incentive Program. Our results argue that policies based
on assuming that physicians are able to predict accu-
rately whether a patient truly has ESRD or not at the
time of RRT initiation may be unwise and unrealistic. A
better approach may be to recognize this diagnostic
uncertainty and modify policy accordingly, such as by
asking physicians to certify patients as having ESRD or
not only after a certain period has elapsed.
Our findings that younger age and higher baseline
eGFR are strong predictors for recovery are consistent
with prior studies.12–15 The fact that chronic liver
disease is associated with reduced chances for recovery
may be due to compromised renal perfusion in the
setting of hepatorenal physiology.48 We speculate that
our finding that higher preadmission hemoglobin level
predicts recovery may reflect higher preadmission
eGFR (because hemoglobin level and eGFR may be
correlated, and our hemoglobin categories were nar-
rower than our eGFR categories) or generally better
health status overall.
Strengths of our study include the large, contem-
porary cohort of patients with AKI-D with broad de-
mographic diversity. Although most other studies have
included only patients in intensive care
units,5,12,16,49,50 our cohort included both intensive
care unit and medical ward patients in 21 medical
centers across Northern California.23 KPNC’s integrated
health care delivery system offers the advantage of
being able to track recovery longitudinally both during
the AKI-D hospitalization and in the outpatient setting577
CLINICAL RESEARCH BJ Lee et al.: Predicting Recovery After AKI-Dafter hospital discharge. In addition, it provides the
unique opportunity to ascertain preadmission comor-
bidities, medication use, and laboratory values. In
contrast, many AKI epidemiology studies2,51,52 have
had limited ascertainment of key clinical covariates
before hospitalization. We used rigorous criteria to
identify AKI-D cases and were careful about requiring
patient survival for $4 weeks after dialysis discon-
tinuation to avoid misclassification of withdrawal of
care as recovery. Our approach of anchoring recovery
from time of dialysis initiation rather than time of
hospital discharge also enhances our results’ general-
izability compared with prior studies because timing of
hospital discharge may be affected by social and
systems-based factors unrelated to the natural history
of AKI-D. Finally, we used 2 modeling techniques to
try to enhance our ability to predict renal recovery.
Several limitations should be noted. Because pre-
dicting recovery is clinically relevant only once pa-
tients are improving, typically in the denouement
phase of acute illness, the ideal study population in
which to derive a prediction rule should include only
patients with AKI-D who reach this juncture in their
hospitalizations. However, it is not possible to identify
this stage of disease trajectory in large database studies
such as ours. We therefore limited our study popula-
tion to the subset of patients with AKI-D who could be
readily identified clinically as not having excessively
high predicted inpatient mortality risk. We did not
want to limit our study population only to AKI-D
survivors because such an approach would use retro-
spective conditioning. We required that all cases of
AKI-D have a $50% increase in serum creatinine over
the preadmission baseline value to reduce misclassifi-
cation of progressive CKD as AKI. However, as a result,
we may have excluded some cases of true AKI-D (e.g., a
cardiac surgery patient who is anuric and volume-
overloaded postoperatively may initiate RRT in the
setting of true AKI but may not meet this threshold to
be included in our analysis). We defined recovery as a
dichotomous outcome based on RRT dependence and
did not estimate magnitude of recovery (e.g., full vs.
partial recovery). Although functional recovery
beyond RRT dependence is certainly important, defi-
nitions for recovery are variable,22 and serum creati-
nine levels may be affected by dilution from fluid
accumulation53 and fluctuating creatinine produc-
tion,54,55 which makes evaluating recovery as a change
in serum creatinine concentration from before to after
the acute illness less straightforward. Furthermore, in
current practice, most physicians do not systematically
ascertain for recovery. Another limitation of our study
was that not all clinical details related to the AKI-D
hospitalizations were available. We were missing578information regarding etiology of preexisting CKD,
indication for RRT initiation, initial RRT modality (e.g.,
intermittent vs. continuous therapy), physiologic var-
iables at time of RRT initiation including APACHE
score and urine output, inpatient medication use, and
setting of AKI (e.g., sepsis or postsurgery); however,
there is no definitive evidence that dialysis dura-
tion,12,56 dialysis dose,57,58 choice of dialysis mem-
brane,59 RRT modality,9,12,56,59–64 timing of dialysis
initiation,65–68 or medications such as diuretics69–71 are
associated with chances of recovery. Although the
specific etiology of AKI-D was also unavailable in our
dataset, prior chart review of KPNC medical records by
a board-certified nephrologist of similar cases showed
that almost all were due to acute tubular necrosis.13,15
We were not able to examine whether the Charlson
comorbidity index and APACHE II score were predic-
tive for recovery, as previously reported,18 because not
all of the components were available. However, the
vast majority of these scores’ parameters are accounted
for in the validated KPNC inpatient mortality score that
was used instead.26 Finally, while we used a 10-fold
cross-validation approach, our results should be
further validated in other external patient populations
that have similarly broad diversity in sociodemo-
graphic features and comorbidity burden.
In conclusion, we have developed and cross-validated a
prediction model for recovery after AKI-D, but our find-
ings reiterate the need for better clinical prediction tools.
Although ourmodel demonstrates excellent calibration, its
modest discrimination may reflect the complexity of fac-
tors affecting recovery. The addition of selected bio-
markers to clinical parameters may prove useful in
enhancing predictive models in the future.18,72,73 Future
research is needed to enhance our predictive abilities as
well as to examine potential treatments that may enhance
or expedite recovery after AKI-D.DISCLOSURE
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